Patients diagnosed with advanced solid tumors treated with combination therapy comprising spartanzumab (anti-PD-1 mAb) and sabezumab (anti-TIM-3 mAb) have shown a decent safety profile and encouraging anti-tumor benefits in phase I/II clinical studies [2, 25]. Here, HAVCR2 is linked to neoplasm.